Skip to main content

Axenoll

HardwareJena, GermanyFounded 2018· One of 1708 Hardware companies tracked by AMPulse

A high-resolution 3D screen printing and bioprinting technology company that designs, develops, and manufactures advanced solutions for medical, life science, and cosmetic applications using gentle additive manufacturing processes.

CEO / Founder
Lutz Freiwald
Team Size
11-50
Stage
Active
Total Funding
$8.26M
Latest Round
Venture Round
Key Investors
Xlife Sciences AG

Technology & Products

Key Products

["Patient-specific bioactive/resorbable implants","Multifunctional wound dressings with drug release","3D multilayer microfluidic chips and Lab-on-a-Chip systems","Bioprinting platforms with living cells for tissue models","Cell scaffolds for tissue engineering","Personalized cosmetic facial masks and skincare products","Drug delivery systems (transdermal, mucosal, targeted)","Organ-on-a-Chip systems for drug testing","Smart textiles with integrated sensors","Surgical guides and biocompatible sensor carriers"]

Technological Advantage

Modular system architecture enables uncomplicated upscaling for mass customization. Technology offers parallel processing of various geometries in single runs, low-temperature processing for sensitive materials, and combination of fine-to-coarse structures. Provides complete service from feasibility studies through R&D, prototyping, and serial production under GMP/sterile conditions. In-house capabilities include paste formulation, screen design, process optimization, and quality management. Offers flexible business models including contract manufacturing, technology transfer, and licensing.

Differentiation

Value Proposition

Enables reproducible, scalable production of complex 3D structures with exceptional material flexibility including living cells, under GMP and sterile conditions. Offers complete development-to-manufacturing pipeline with ability to print diverse materials (polymers, biomaterials, ceramics, metals) and combine synthetic with biological components seamlessly.

How They Differentiate

Exclusive global license for Exentis 3D Mass Customization® technology enabling high-resolution 3D screen printing of cellular/molecular materials under GMP conditions; unique capability to process living cells while maintaining viability through gentle low-temperature processing; complete end-to-end service from R&D to serial production

Market & Competition

Target Customers

Medical device manufacturers, pharmaceutical companies, biotechnology firms, cosmetics companies, research institutions, and organizations requiring custom bioprinting, microfluidic devices, or specialized medical products

Industry Verticals

["Medical Technology","Pharmaceuticals","Life Sciences","Biotechnology","Cosmetics","Microfluidics","Regenerative Medicine","Wearables & Smart Textiles"]

Competitors

BICO Group AB (CELLINK); 3D Systems Corporation; Aspect Biosystems

Growth & Milestones

Growth Metrics

€9M balance sheet total (2023); 10-50 employees; established commercial operations with serial production capabilities

Major Milestones

["Exclusive global licensing agreement for Exentis 3D Mass Customization® technology","Strategically significant patent granted by European Patent Office for biological tissue generation process (Jan 2023)","$8.26M venture capital investment secured (Jul 2021)","Established GMP-compliant manufacturing capabilities","Multiple R&D projects funded by German and Swiss research programs"]

Notable Customers

Medical device manufacturers; Pharmaceutical companies; Biotechnology firms; Research institutions

https://axenoll.com

Why this company matters

Axenoll occupies a narrow but defensible niche in additive manufacturing: high-resolution 3D screen printing of paste-formable materials, including living cells, under GMP and sterile conditions. Unlike extrusion-based bioprinters that struggle with throughput or cell viability, Axenoll's process relies on a modular screen-printing architecture licensed exclusively from Exentis Group AG. This allows parallel fabrication of multiple geometries in a single run, low-temperature processing for sensitive biologics, and the combination of synthetic and biological components in one structure.

The company's core offering is a complete development-to-manufacturing pipeline, from feasibility studies and paste formulation through prototyping to serial production. Products include patient-specific bioactive implants, multifunctional wound dressings with drug release, multilayer microfluidic and organ-on-a-chip systems, cell scaffolds, and personalized cosmetic masks. Axenoll processes polymers, biomaterials, ceramics, and metals, but its distinctive capability is maintaining cell viability during printing, which opens applications in regenerative medicine and drug testing that conventional LPBF or SLA cannot address.

Axenoll serves medical device manufacturers, pharmaceutical and biotechnology firms, cosmetics companies, and research institutions. It operates as a B2B service provider and technology licensee rather than a platform developer, which differentiates it from bioprinting competitors such as BICO Group (CELLINK) and Aspect Biosystems. Backed by Xlife Sciences AG and supported by German and Swiss research programs, the company has established GMP-compliant serial production and holds European patents for a microneedle device and a biological tissue generation process.

The strategic moat rests on the exclusive global license for Exentis 3D Mass Customization technology and the ability to combine synthetic and biological materials in sterile, scalable production. The open question is whether the screen-printing approach can achieve the resolution and throughput demanded by large pharmaceutical customers, or whether it will remain a specialized tool for small-batch, high-value regenerative medicine products.